Microdosing:
Microdosing an alternative approach to study the behavior of drugs in humans through the administration of doses in low concentration, as they are unlikely to produce the complete-body effects, but high enough to allow the cellular response to be studied.It may be said as the less than one hundredth of the proposed pharmacological dose This is called a Phase zero study and is usually conducted before clinical Phase I to predict whether a drug is viable for the next phase of testing. Microdosing on Humans aims to cut short the resources spent on non-viable drugs and the amount of testing done on animals and experimental trials. Microdosing studies enable potential new drugs to be tested safely in humans using accelerator mass spectrometry. The technique has been developed commercially trials were conducted with several major pharmaceutical companies It is reported that 15 among the 20 largest pharmaceutical companies have now used microdosing as a new trend in drug development, and the use of the technique has been provisionally endorsed by both the Medicinal Agency of Europe and the Food and Drug Administration.
Subtracks:
1. Radioisotope carbon
2. Accelerator Mass Spectrometry
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
